Neuroblastoma staging shapes every downstream decision, from induction intensity to surgical timing to eligibility at relapse. The shift from INSS to the INRG Staging System changed the mechanics of that workup at diagnosis. Legacy records, ongoing trials, and cross-institutional referrals still surface INSS language across pediatric oncology practice.
Practical staging happens at diagnosis through imaging selection, IDRF documentation, bilateral marrow assessment, and MIBG protocol execution. Each step carries clinical implications for the treating team and the referring institution across the care pathway. The sections ahead cover the framework shift, workup mechanics, and how staging feeds treatment planning.
What Is the Difference Between INSS and INRG Staging for Neuroblastoma?
INSS classified neuroblastoma based on surgical findings, particularly resection completeness, making stage assignment vulnerable to variation in surgical approach. INRGSS replaced that framework with imaging-based pretreatment staging built around image-defined risk factors documented at diagnosis. The shift aligned staging with underlying biology rather than with the outcome of the initial operation.
How INRGSS Replaced INSS in Modern Neuroblastoma Staging
INSS anchored stage assignment to what the surgeon found in the operating room, which introduced variability across institutions. INRGSS moved neuroblastoma staging upstream to pretreatment imaging, aligning classification with tumor biology rather than surgical technique. The shift reshaped how teams approach staging at the point of diagnosis across cooperative group practice.
The four INRGSS stages replaced the six-tier INSS structure with a cleaner framework built around imaging findings at diagnosis. L1 captures localized disease without any image-defined risk factors documented on cross-sectional imaging at diagnosis. L2 captures localized disease with one or more such factors documented at diagnosis.
M covers distant metastatic disease outside the criteria for stage MS across pediatric and adult presentations. MS applies to metastatic disease in children under 18 months confined to skin, liver, or bone marrow. Each stage distinction carries different prognostic weight and shapes induction planning across treating centers.
Legacy INSS language persists across older records, published trial data, and cross-institutional referrals in pediatric oncology. Teams working across both frameworks need fluency in each to interpret patient histories accurately. Dual literacy supports both new patient intake and analysis of historical cohorts across the field.
Image-Defined Risk Factors and Their Role in Stage Assignment
Image-defined risk factors anchor neuroblastoma staging within the INRGSS framework at the point of diagnosis. Each factor reflects an anatomical feature visible on diagnostic imaging that signals surgical risk to the treating team. Their presence or absence separates L1 disease from L2 disease across localized presentations.
- Vascular encasement covers tumor contact with or encirclement of the aorta, vena cava, or major branch vessels.
- Airway and mediastinal involvement includes tracheal or bronchial compression and infiltration of adjacent mediastinal structures.
- Spinal canal extension reflects intraspinal tumor invasion visible on cross-sectional imaging at diagnosis.
- Adjacent organ infiltration captures direct extension into kidney, liver, pancreas, or other neighboring viscera at the primary site.
- Cross-compartment or multifocal involvement flags tumors spanning multiple body compartments or presenting at multiple primary sites.
Documentation of these factors happens through CT or MRI reviewed at diagnosis before any surgical intervention on the primary tumor. The factors carry independent prognostic weight, so two patients at the same INRGSS stage can follow different surgical courses. Anatomical variation feeds directly into the treatment planning conversation with the family at the treating institution.
Executing the Staging Workup at Diagnosis
Neuroblastoma staging at diagnosis combines cross-sectional imaging, functional imaging, and bone marrow assessment across a defined sequence. Each modality contributes distinct information that feeds the final stage assignment and downstream risk classification. Coordinated execution reduces delays between diagnosis and treatment initiation across the care team.
Cross-sectional imaging with CT or MRI documents the primary tumor and identifies image-defined risk factors across relevant anatomical regions. MIBG scintigraphy assesses functional uptake across skeletal and soft tissue sites, capturing metastatic disease that anatomical imaging alone may miss. Bilateral bone marrow aspirates and biopsies confirm marrow involvement across both iliac crests at the point of diagnosis.
The sequencing of these studies matters for both accuracy and efficiency across the workup. Complete cross-sectional imaging before biopsy planning reduces the risk of missing image-defined risk factors on retrospective review. MIBG timing aligns with the isotope infusion protocol at the treating center to support optimal image quality.
Documentation of each finding travels together as the staging package for the referring team and any downstream cooperative group enrollment. Complete records reduce repeat imaging and expedite treatment decisions across the care pathway.
How Neuroblastoma Staging Feeds Risk Classification and Treatment Planning
Neuroblastoma staging feeds directly into INRG risk classification alongside age, MYCN status, ploidy, and histology at diagnosis. Risk classification then anchors induction intensity, surgical timing, and eligibility for on-label therapies at relapse. Stage assignment shapes every subsequent decision on the treatment pathway across the care team.
Stage at diagnosis carries weight for identifying patients who may develop bone or bone marrow involvement later. According to DuBois (1999), 70 percent of metastases involve the bone marrow, and 55 percent involve cortical bone. Metastatic distribution shapes surveillance planning and downstream therapy consideration across the care pathway.
Communication of stage across the care team matters as much as the assignment itself for aligned patient management. Shared staging vocabulary reduces friction at handoff and supports both new intake and ongoing management across institutions.
Ongoing documentation across the treatment course supports both individual patient management and the shared evidence base. Registry participation strengthens that record across treating institutions and advances the science supporting classification updates. Consistent reporting across centers builds the confirmatory data required for future revisions of the INRG framework.
Partner With SERB to Advance Neuroblastoma Staging Accuracy Across Your Center
Accurate neuroblastoma staging at diagnosis anchors every downstream decision, from induction intensity through surgical planning to relapse eligibility. The INRGSS framework replaced INSS with imaging-based staging built around image-defined risk factors documented before surgery. Dual fluency with legacy INSS language remains essential for interpreting older records and cross-institutional referrals across pediatric oncology.
Consistent execution of the staging workup supports both individual patient care and the shared evidence base across cooperative group practice. Registry participation strengthens that record across treating institutions and advances the science supporting classification updates. Connect with SERB to access clinical resources that support your team through the staging and treatment pathway.
Sources
DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. Journal of Pediatric Hematology/Oncology. 1999;21(3):181-189.
